Unity Biotechnology, Inc. Contracts & Agreements

Third Amended and Restated Non-Employee Director Compensation Program (Filed With SEC on April 15, 2024)

Form of New Warrant (Filed With SEC on November 13, 2023)

Form of Inducement Letter (Filed With SEC on November 13, 2023)

Amendment No. 2 to Sales Agreement, dated March 17, 2023, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC (Filed With SEC on March 17, 2023)

Form of Common Stock Certificate (Filed With SEC on November 8, 2022)

Form of Warrant (Filed With SEC on August 22, 2022)

Underwriting Agreement, dated as of August 17, 2022, among Unity Biotechnology, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as... (Filed With SEC on August 22, 2022)

Amendment No. 1 to Sales Agreement, dated August 17, 2022, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC (Filed With SEC on August 19, 2022)

Press release titled UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of -Klotho Program (Filed With SEC on December 20, 2021)

Amendment No. 1 to Loan and Security Agreement, dated December 15, 2021, by and between the Company and Hercules Capital, Inc (Filed With SEC on December 15, 2021)

Registration Rights Agreement, dated September 29, 2021, by and between the Company and Lincoln Park (Filed With SEC on September 29, 2021)

Purchase Agreement, dated September 29, 2021, by and between the Company and Lincoln Park (Filed With SEC on September 29, 2021)

Employment Agreement, dated March 8, 2021, by and between Unity Biotechnology, Inc. and Alexander Nguyen (Filed With SEC on May 11, 2021)

Amendment to APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd (Filed With SEC on March 23, 2021)

Amended and Restated License Agreement, dated as of January 27, 2017, by and between the Buck Institute for Research on Aging and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Amendment No. 5 to Exclusive License Agreement, dated as of October 17, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Addendum to Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity... (Filed With SEC on March 23, 2021)

Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Amendment No. 3 to Exclusive License Agreement, dated as of May 5, 2015, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Amendment No. 1 to Exclusive License Agreement, dated as of September 10, 2014, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Exclusive License Agreement, dated as of June 28, 2013, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Amendment to Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

License Agreement, dated as of November 3, 2016, by and between The Johns Hopkins University and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Transition and Separation Agreement, dated December 12, 2020, by and between Nathaniel David and Unity Biotechnology, Inc (Filed With SEC on March 23, 2021)

Amendment to Executive Employment Agreement, dated September 1, 2020, by and between Unity Biotechnology, Inc. and Lynne Sullivan (Filed With SEC on November 4, 2020)

Executive Employment Agreement, dated August 1, 2020, by and between Unity Biotechnology, Inc. and Lynne Sullivan (Filed With SEC on November 4, 2020)

Loan and Security Agreement dated August 3, 2020 between Unity Biotechnology, Inc. and Hercules Capital, Inc (Filed With SEC on August 4, 2020)

Sales Agreement, dated July 31, 2020, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC (Filed With SEC on July 31, 2020)

Third Amendment to Compound License Agreement for APG-1197, dated June 29, 2020, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on July 1, 2020)

Amended and Restated Non-Employee Director Compensation Program (effective as of March 30, 2020) (Filed With SEC on May 7, 2020)

Employment Agreement, dated March 30, 2020, by and between Unity Biotechnology, Inc. and Anirvan Ghosh (Filed With SEC on March 30, 2020)

Second Amendment to APG1252 License Agreement, dated as of November 19, 2019, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on March 11, 2020)

Amendment to Employment Agreement, dated March 9, 2020, by and between Unity Biotechnology, Inc. and Tamara L. Tompkins (Filed With SEC on March 11, 2020)

Amendment to Employment Agreement, dated March 9, 2020, by and between Unity Biotechnology, Inc. and Daniel G. Marquess (Filed With SEC on March 11, 2020)

Amendment to Employment Agreement, dated March 9, 2020, by and between Unity Biotechnology, Inc. and Jamie Dananberg (Filed With SEC on March 11, 2020)

Amendment to Employment Agreement, dated March 9, 2020, by and between Unity Biotechnology, Inc. and Robert C. Goeltz II (Filed With SEC on March 11, 2020)

Amendment to Employment Agreement, dated March 9, 2020, by and between Unity Biotechnology, Inc. and Nathaniel E. David (Filed With SEC on March 11, 2020)

Second Amendment to Compound Library and Option Agreement, dated as of January 8, 2020, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on March 11, 2020)

Description of Unitys Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 11, 2020)

First Amendment to Compound License Agreement for APG1197, dated as of November 19, 2019, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on November 25, 2019)

Amended and Restated Non-Employee Director Compensation Program (effective as of June 13, 2019) (Filed With SEC on August 7, 2019)

Amended and Restated Non-Employee Director Compensation Program (effective as of March 14, 2019) (Filed With SEC on May 8, 2019)

License Agreement for APG1197, dated as of January 2, 2019, by and between Ascentage Pharma Group Corp. Ltd. And Unity Biotechnology, Inc (Filed With SEC on March 6, 2019)

Amended and Restated Non-Employee Director Compensation Program (Effective January 1, 2019) (Filed With SEC on March 6, 2019)

Amended and Restated 2018 Employee Stock Purchase Plan (Filed With SEC on November 7, 2018)

2018 Incentive Award Plan (Filed With SEC on April 23, 2018)

Form of Underwriting Agreement (Filed With SEC on April 23, 2018)

License Agreement, dated as of November 3, 2016, by and between The Johns Hopkins University and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Amended and Restated License Agreement, dated as of January 27, 2017, by and between the Buck Institute for Research on Aging and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Amendment No. 5 to Exclusive License Agreement, dated as of October 17, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Addendum to Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity... (Filed With SEC on April 23, 2018)

Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Amendment No. 2 to Exclusive License Agreement, dated as of November 17, 2014, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Form of Common Stock Certificate (Filed With SEC on April 23, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on April 23, 2018)

Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Amendment No. 3 to Exclusive License Agreement, dated as of May 5, 2015, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Amendment No. 1 to Exclusive License Agreement, dated as of September 10, 2014, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Exclusive License Agreement, dated as of June 28, 2013, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 23, 2018)

Form of Indemnification Agreement for directors and officers (Filed With SEC on April 5, 2018)

Amendment to Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 5, 2018)

Amendment to APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and (Filed With SEC on April 5, 2018)

Research Services Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 5, 2018)

APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 5, 2018)

Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Tamara L. Tompkins (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Daniel G. Marquess (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Jamie Dananberg (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Robert C. Goeltz II (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Nathaniel E. David (Filed With SEC on April 5, 2018)

Employment Agreement, dated January 29, 2018, by and between Unity Biotechnology, Inc. and Keith R. Leonard Jr (Filed With SEC on April 5, 2018)

Non-Employee Director Compensation Program (Filed With SEC on April 5, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on April 5, 2018)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan (Filed With SEC on April 5, 2018)

Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2018 Incentive Award Plan (Filed With SEC on April 5, 2018)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan (Filed With SEC on April 5, 2018)

2018 Incentive Award Plan (Filed With SEC on April 5, 2018)

Form of Stock Option Agreement under 2013 Equity Incentive Plan (Filed With SEC on April 5, 2018)

2013 Equity Incentive Plan (Filed With SEC on April 5, 2018)

Second Amendment to Space License Agreement, dated as of January 30, 2017, by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P (Filed With SEC on April 5, 2018)

First Amendment to Space License Agreement, dated as of December 5, 2016, by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P (Filed With SEC on April 5, 2018)

Space License Agreement, dated as of October 20, 2016, by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P (Filed With SEC on April 5, 2018)

First Amendment to Lease Agreement, dated as of May 23, 2017, by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P (Filed With SEC on April 5, 2018)

Lease Agreement, dated as of May 13, 2016, by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P (Filed With SEC on April 5, 2018)

Amended and Restated Investors Rights Agreement, dated as of March 15, 2018, by and among Unity Biotechnology, Inc. and the investors party thereto (Filed With SEC on April 5, 2018)

Category

Industry

Companies

Contracts

Unity Biotechnology, Inc. Contracts & Agreements